WO2017062500A2 - Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies - Google Patents

Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies Download PDF

Info

Publication number
WO2017062500A2
WO2017062500A2 PCT/US2016/055561 US2016055561W WO2017062500A2 WO 2017062500 A2 WO2017062500 A2 WO 2017062500A2 US 2016055561 W US2016055561 W US 2016055561W WO 2017062500 A2 WO2017062500 A2 WO 2017062500A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
group
optionally substituted
salt
racemate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2016/055561
Other languages
English (en)
French (fr)
Other versions
WO2017062500A3 (en
Inventor
Kirsten Alison Rinderspacher
Wai Yu
Karen Duff
Donald Landry
Shi-Xian Deng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ny State Psychiatric Institute
Columbia University in the City of New York
Original Assignee
Ny State Psychiatric Institute
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2018004109A priority Critical patent/MX2018004109A/es
Priority to JP2018536715A priority patent/JP6740354B2/ja
Priority to BR112018006873-0A priority patent/BR112018006873A2/pt
Priority to CN201680062131.XA priority patent/CN108473435A/zh
Priority to EP16854245.4A priority patent/EP3359526A4/en
Priority to US15/765,801 priority patent/US20190112317A1/en
Application filed by Ny State Psychiatric Institute, Columbia University in the City of New York filed Critical Ny State Psychiatric Institute
Priority to CA3000988A priority patent/CA3000988A1/en
Priority to AU2016333987A priority patent/AU2016333987A1/en
Priority to KR1020187012344A priority patent/KR20180086187A/ko
Priority to US15/480,220 priority patent/US10487091B2/en
Publication of WO2017062500A2 publication Critical patent/WO2017062500A2/en
Publication of WO2017062500A3 publication Critical patent/WO2017062500A3/en
Priority to JP2019518267A priority patent/JP2019529514A/ja
Priority to PCT/US2017/054969 priority patent/WO2018067589A1/en
Priority to EP17859036.0A priority patent/EP3523281A4/en
Priority to KR1020197012934A priority patent/KR20190058620A/ko
Priority to AU2017338769A priority patent/AU2017338769A1/en
Priority to BR112019006887A priority patent/BR112019006887A2/pt
Priority to MX2019003805A priority patent/MX2019003805A/es
Priority to CA3037260A priority patent/CA3037260A1/en
Priority to CN201780064731.4A priority patent/CN110023289A/zh
Priority to IL258498A priority patent/IL258498A/en
Anticipated expiration legal-status Critical
Priority to ZA2018/02294A priority patent/ZA201802294B/en
Priority to US16/027,930 priority patent/US11008341B2/en
Priority to US16/027,951 priority patent/US11230558B2/en
Priority to US16/027,990 priority patent/US10865214B2/en
Priority to ZA2019/01694A priority patent/ZA201901694B/en
Priority to IL265750A priority patent/IL265750B/en
Priority to US16/818,388 priority patent/US11261199B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/93—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Definitions

  • the present disclosure relates to compounds which are activators of autophagic flux and pharmaceutical compositions comprising said compounds. It further relates to use of said compounds in the treatment of neurodegenerative diseases, particularly Alzheimer's disease.
  • AD Alzheimer's disease
  • AD Alzheimer's disease
  • tau the other major neuropathological component of AD.
  • AD accounts for most of the dementias afflicting individuals over 65 and is estimated to cost $226 billion in healthcare, long-term care, and hospice for people with AD and other dementias annually. This extensive economic and societal burden does not account for lost income of many at-home primary caregivers including spouses and other family members.
  • a pharmaceutical composition comprising a compound disclosed herein or a pharmaceutically acceptable salt thereof.
  • methods of making the compounds and pharmaceutical compositions are also provided in, e.g., the Examples provided below.
  • a method of treating a neurodegenerative disease comprising administering to a subject in need thereof an effective amount of a compound or pharmaceutical composition disclosed herein is provided.
  • a method of enhancing autophagic flux comprises providing to a cell or a protein aggregate an effective amount of a compound or pharmaceutical composition disclosed herein.
  • FIG. 1 is a graph showing a photodiode array (PDA) spectrum of WHYKD8 in mouse brain.
  • FIG. 2 shows Western blots of LC3-II levels in primary cortical neurons following a 6 hour treatment with WHYKD 1 ( ⁇ BafA1 ) or WHYKD5.
  • FIG. 3 shows Western blots of LC3-II, tau, and p62 levels in organotypic slice cultures following a 6 hour treatment with WHYKD 1 (top) or WHYKD3, WHYKD5, WHYKD8, WHYKD9, or WHYKD12 (bottom).
  • FIG. 4 is a bar graph showing the activation of phospholipase D (PLD) by the WHYKD series compounds (10 ⁇ ), and their ability to convert phospholipids to phosphatidylethanols in the presence of ethanol.
  • C Control
  • 12 WHYKD12
  • 15 WHYKD
  • 19 WHYKD 19
  • 5 WHYKD5
  • 8 WHYKD8
  • Fipi a noncompetitive inhibitor of PLD activity.
  • FIG. 5 is a bar graph showing the activation of phospholipase D (PLD) by the WHYKD series compounds (1 ⁇ ), and their ability to convert phospholipids to phosphatidylethanols in the presence of ethanol.
  • PLD phospholipase D
  • PLD1 The localization of PLD1 , as well as the starvation-induced increase in PLD activity, are altered by wortmannin, a phosphatidylinositol 3-kinase inhibitor, suggesting PLD1 may act downstream of Vps34.
  • Pharmacological inhibition of PLD and genetic ablation of PLD1 in mouse cells decreased the starvation-induced expansion of LC3-positive compartments, consistent with a role of PLD1 in the regulation of autophagy.
  • inhibition of PLD results in higher levels of tau and p62 aggregates in organotypic brain slices.
  • Y 1 and Y 2 are independently selected from the group consisting of CH and N;
  • X is selected from the group consisting of H, halide, and aryl
  • R 1 is selected from the group consisting of optionally substituted thioheteroaryl, hydroxyl-substituted (2-aminoethyl)aryl, halide, optionally substituted thiocycloalkyi wherein 1 -3 carbon atoms of the cycloalkyi is optionally replaced with a heteroatom selected from the group consisting of O, S and N, and thioaryl, or a salt, enantiomer, racemate, mixture thereof, or combination thereof.
  • the compound is selected from the group consisting of:
  • the compound is:
  • the compound is:
  • Y 1 is CH
  • R 1 is selected from the group consisting of optionally substituted thioheteroaryl, optionally substituted (2-aminoethyl)aryl, halide, optionally substituted thiocycloalkyi wherein 1 -3 carbon atoms of the cycloalkyi is optionally replaced with a heteroatom selected from the group consisting of O, S and N, and thioaryl, or a salt, enantiomer, racemate, mixture thereof, or combination thereof.
  • the compound is selected from the group consisting of optionally substituted thioheteroaryl, optionally substituted (2-aminoethyl)aryl, halide, optionally substituted thiocycloalkyi wherein 1 -3 carbon atoms of the cycloalkyi is optionally replaced with a heteroatom selected from the group consisting of O, S and N, and thioaryl, or a salt, enantiomer, racemate, mixture thereof, or combination thereof.
  • the compound is selected
  • R 1 is selected from the group consisting of optionally substituted thioheteroaryl, optionally substituted (2-aminoethyl)aryl, halide, optionally substituted thiocycloalkyi wherein 1 -3 carbon atoms of the cycloalkyi is optionally replaced with a heteroatom selected from the group consisting of O, S and N, and thioaryl, or a salt, enantiomer, racemate, mixture thereof, or combination thereof.
  • the compound is selected from the group consisting of:
  • R 1 is selected from the group consisting of optionally substituted thioheteroaryl, optionally substituted (2-aminoethyl)aryl, halide, optionally substituted thiocycloalkyi wherein 1 -3 carbon atoms of the cycloalkyi is optionally replaced with a heteroatom selected from the group consisting of O, S and N, and thioaryl, or a salt, enantiomer, racemate, mixture thereof, or combination thereof.
  • the compound is selected from the group consisting of:
  • R 1 is selected from the group consisting of optionally substituted thioheteroaryl, optionally substituted (2-aminoethyl)aryl, halide, optionally substituted thiocycloalkyi wherein 1 -3 carbon atoms of the cycloalkyi is optionally replaced with a heteroatom selected from the group consisting of O, S and N, and thioaryl, or a salt, enantiomer, racemate, mixture thereof, or combination thereof.
  • the compound is selected from the group consisting of:
  • R 1 is selected from the group consisting of optionally substituted thioheteroaryl, optionally substituted (2-aminoethyl)aryl, halide, optionally substituted thiocycloalkyi wherein 1 -3 carbon atoms of the cycloalkyi is optionally replaced with a heteroatom selected from the group consisting of O, S and N, and thioaryl, or a salt, enantiomer, racemate, mixture thereof, or combination thereof.
  • the compound is selected from the group consisting of:
  • R 1 is selected from the group consisting of optionally substituted thioheteroaryl, optionally substituted (2-aminoethyl)aryl, halide, optionally substituted thiocycloalkyi wherein 1 -3 carbon atoms of the cycloalkyi is optionally replaced with a heteroatom selected from the group consisting of O, S and N, and thioaryl, or a salt, enantiomer, racemate, mixture thereof, or combination thereof.
  • the compound is selected from the group consisting of:
  • Y 3 is CH or N
  • R 2 is optionally substituted (2-aminoethyl)aryl
  • the compound is selected from the group consisting of:
  • Y 3 is CH
  • R 2 is selected from the group consisting of optionally substituted thioheteroaryl, optionally substituted (2-aminoethyl)aryl, halide, optionally substituted thiocycloalkyi wherein 1 -3 carbon atoms of the cycloalkyi is optionally replaced with a heteroatom selected from the group consisting of O, S and N, and thioaryl, or a salt, enantiomer, racemate, mixture thereof, or combination thereof.
  • the compound is selected from the group consisting of:
  • R 2 is selected from the group consisting of optionally substituted thioheteroaryl, optionally substituted (2-aminoethyl)aryl, halide, optionally substituted thiocycloalkyi wherein 1 -3 carbon atoms of the cycloalkyi is optionally replaced with a heteroatom selected from the group consisting of O, S and N, and thioaryl, or a salt, enantiomer, racemate, mixture thereof, or combination thereof.
  • the compound is selected from the group consisting of:
  • Y is CH or N
  • R is selected from the group consisting of optionally substituted thioheteroaryl, optionally substituted (2-aminoethyl)aryl, halide, optionally substituted thiocycloalkyi wherein 1 -3 carbon atoms of the cycloalkyi is optionally replaced with a heteroatom selected from the group consisting of O, S and N, and thioaryl, or a salt, enantiomer, racemate, mixture thereof, or combination thereof.
  • the compound is selected from the group consisting of:
  • R 2 is selected from the group consisting of optionally substituted thioheteroaryl, optionally substituted (2-aminoethyl)aryl, halide, optionally substituted thiocycloalkyi wherein 1 -3 carbon atoms of the cycloalkyi is optionally replaced with a heteroatom selected from the group consisting of O, S and N, and thioaryl, or a salt, enantiomer, racemate, mixture thereof, or combination thereof.
  • the compound is selected from the group consisting of:
  • R 2 is selected from the group consisting of optionally substituted thioheteroaryl, optionally substituted (2-aminoethyl)aryl, halide, optionally substituted thiocycloalkyi wherein 1 -3 carbon atoms of the cycloalkyi is optionally replaced with a heteroatom selected from the group consisting of O, S and N, and thioaryl, or a salt, enantiomer, racemate, mixture thereof, or combination thereof.
  • the compound is selected from the group consisting of:
  • X is H or halide
  • Z 1 is O
  • R 4 is selected from the group consisting of H, optionally substituted alkyl, Et, CF 3 , optionally substituted cycloalkyl, optionally substituted aryl, optionally
  • the compound is selected from the group consisting of:
  • a pharmaceutical composition comprising a compound disclosed herein or a pharmaceutically acceptable salt thereof.
  • a method of treating a neurodegenerative disease comprising administering to a subject in need thereof an effective amount of a compound or pharmaceutical composition disclosed herein is provided.
  • the neurodegenerative disease is a proteinopathy.
  • Proteinopathies include, but are not limited to, Parkinson's disease, Alzheimer's disease, Amyotrophic Lateral Sclerosis (ALS), Huntington's disease, chronic traumatic encephalopathy (CTE), frontotemporal dementia (FTD), inclusion body myopathy (IBM), Paget's disease of bone (PDB), cerebral ⁇ -amyloid angiopathy, prion diseases, familial dementia, CADASIL, amyloidosis, Alexander disease, seipinopathies, type II diabetes, pulmonary alveolar proteinosis, cataracts, cystic fibrosis and sickle cell disease.
  • Parkinson's disease Alzheimer's disease, Amyotrophic Lateral Sclerosis (ALS), Huntington's disease, chronic traumatic encephalopathy (CTE), frontotemporal dementia (FTD), inclusion body myopathy (IBM
  • the proteinopathy is a tauopathy.
  • Tauopothies include but are not limited to, Alzheimer's disease, Parkinson's disease, Huntington's disease, progressive supranuclear palsy, chronic traumatic encephalopathy (CTE), frontotemporal dementia (FTD), Lytico- Bodig disease, subacute sclerosing panencephalitis, ganglioglioma, gangliocytoma, and argyrophilic grain disease.
  • the neurodegenerative disease is Alzheimer's disease.
  • a method of enhancing autophagic flux comprises providing to a cell or a protein aggregate an effective amount of a compound or pharmaceutical composition disclosed herein.
  • Example 1 The following examples are provided to further illustrate certain aspects of the present invention. These examples are illustrative only and are not intended to limit the scope of the invention in any way.
  • Example 1
  • X H, F, CI, Br, I, CH 3 , CF 3
  • R 1 H, alkyl, cycloalkyl, aryl, heteroaryl
  • Scheme 2 shows preparation of 1 -chloro-7-fluoroisoquinoline.
  • R 1 ⁇ , alkyl, cycloalkyi, aryl, heteroaryl
  • R 1 H, alkyl, cycloalkyi, aryl, heteroaryl
  • R 1 H, alkyl, cycloalkyi, aryl, heteroaryl
  • R 1 H, alkyl, cycloalkyl, aryl, heteroaryl
  • the WHYKD series of compounds were synthesized for optimal brain penetrance based on the molecular weight (MW) and partition coefficient (log P), according to Lipinski's Rule for CNS penetrance: MW ⁇ 400, log P ⁇ 5.
  • Table 7 Modifications to the core and side chain (Series 3)
  • Table 8 Modifications to the core and side chain (Series 4)
  • Table 9 Modifications to the core and side chain (Series 5)
  • Table 10 Modifications to the core and side chain (Series 6)
  • Table 1 1 Modifications to the core and side chain (Series 7)
  • Table 12 Modifications to the core and side chain (Series 8)
  • a photodiode array was used to detect WHYKD8 in mouse brain (FIG. 1 ). The sample was readily detected with a discrete peak based on time (left) and with a measurable area under the curve (AUC) (inset).
  • LC3-II levels were measured in primary cortical neurons following 6 hours of treatment with WHYKD1 , WHYKD5, or WHYKD1 + BafA1 (FIG. 2). The presence of LC3-II is an indication of autophagy.
  • LC3-II levels were then measured in organotypic slice cultures following 6 hours of treatment with WHYKD1 (FIG. 3, top panel). Other compounds in the WHYKD series produced similar results (FIG. 3, bottom panel).
  • RFP is a tag on the tau protein and also can be probed.
  • PLD activation converts phospholipids to phosphatidylethanols in the presence of ethanol. This conversion was measured to show that the WHYKD series of compounds activate PLD at 10 ⁇ concentration (FIG. 4) and at 1 ⁇ (FIG. 5).
  • FIPI is a non-competitive inhibitor of PLD activity and was used as a negative control.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
PCT/US2016/055561 2015-10-05 2016-10-05 Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies Ceased WO2017062500A2 (en)

Priority Applications (27)

Application Number Priority Date Filing Date Title
JP2018536715A JP6740354B2 (ja) 2015-10-05 2016-10-05 オートファジーの流れ及びホスホリパーゼｄ及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法
BR112018006873-0A BR112018006873A2 (pt) 2015-10-05 2016-10-05 ativadores do fluxo autofágico e fosfolipase d e depuração de agregados de proteína incluindo tau e tratamento de proteinopatias
CN201680062131.XA CN108473435A (zh) 2015-10-05 2016-10-05 自噬潮和磷脂酶d的活化剂以及包括tau的蛋白聚集体的清除和蛋白质病的治疗
EP16854245.4A EP3359526A4 (en) 2015-10-05 2016-10-05 ACTIVATORS OF AUTOPHAGIC RIVER AND PHOSPHOLIPASE D AND PURIFICATION OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES
US15/765,801 US20190112317A1 (en) 2015-10-05 2016-10-05 Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
MX2018004109A MX2018004109A (es) 2015-10-05 2016-10-05 Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
CA3000988A CA3000988A1 (en) 2015-10-05 2016-10-05 Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
AU2016333987A AU2016333987A1 (en) 2015-10-05 2016-10-05 Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies
KR1020187012344A KR20180086187A (ko) 2015-10-05 2016-10-05 자가포식 유동의 활성체 및 포스포리파제 d 및 타우를 포함하는 단백질 응집물의 클리어런스 및 단백질질환의 치료
US15/480,220 US10487091B2 (en) 2015-10-05 2017-04-05 Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies
CN201780064731.4A CN110023289A (zh) 2015-10-05 2017-10-03 自噬潮和磷脂酶d的活化剂以及包括tau的蛋白聚集体的清除和蛋白质病的治疗
PCT/US2017/054969 WO2018067589A1 (en) 2015-10-05 2017-10-03 Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
KR1020197012934A KR20190058620A (ko) 2015-10-05 2017-10-03 자가포식 유동의 활성체 및 포스포리파제 d 및 타우를 포함하는 단백질 응집물의 클리어런스 및 단백질질환의 치료
CA3037260A CA3037260A1 (en) 2015-10-05 2017-10-03 Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
EP17859036.0A EP3523281A4 (en) 2015-10-05 2017-10-03 AUTOPHAGIC RIVER AND PHOSPHOLIPASE D ACTIVATORS AND PROTEIN UNIT CLEANING INCLUDING DEW AND TREATMENT OF PROTEINOPATHIA
JP2019518267A JP2019529514A (ja) 2015-10-05 2017-10-03 オートファジーフラックス及びホスホリパーゼｄ及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法
AU2017338769A AU2017338769A1 (en) 2015-10-05 2017-10-03 Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
BR112019006887A BR112019006887A2 (pt) 2015-10-05 2017-10-03 ativadores do fluxo autofágico e fosfolipase d e depuração de agregado proteico, incluindo tau e tratamento de proteinopatias
MX2019003805A MX2019003805A (es) 2015-10-05 2017-10-03 Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
IL258498A IL258498A (en) 2015-10-05 2018-04-04 Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
ZA2018/02294A ZA201802294B (en) 2015-10-05 2018-04-09 Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
US16/027,930 US11008341B2 (en) 2015-10-05 2018-07-05 Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies
US16/027,990 US10865214B2 (en) 2015-10-05 2018-07-05 Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies
US16/027,951 US11230558B2 (en) 2015-10-05 2018-07-05 Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies
ZA2019/01694A ZA201901694B (en) 2015-10-05 2019-03-19 Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
IL265750A IL265750B (en) 2015-10-05 2019-04-01 Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
US16/818,388 US11261199B2 (en) 2015-10-05 2020-03-13 Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562237342P 2015-10-05 2015-10-05
US62/237,342 2015-10-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/480,220 Continuation-In-Part US10487091B2 (en) 2015-10-05 2017-04-05 Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies

Publications (2)

Publication Number Publication Date
WO2017062500A2 true WO2017062500A2 (en) 2017-04-13
WO2017062500A3 WO2017062500A3 (en) 2017-05-26

Family

ID=58488491

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2016/055561 Ceased WO2017062500A2 (en) 2015-10-05 2016-10-05 Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
PCT/US2017/054969 Ceased WO2018067589A1 (en) 2015-10-05 2017-10-03 Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2017/054969 Ceased WO2018067589A1 (en) 2015-10-05 2017-10-03 Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies

Country Status (12)

Country Link
US (6) US20190112317A1 (enExample)
EP (2) EP3359526A4 (enExample)
JP (3) JP6740354B2 (enExample)
KR (2) KR20180086187A (enExample)
CN (2) CN108473435A (enExample)
AU (2) AU2016333987A1 (enExample)
BR (2) BR112018006873A2 (enExample)
CA (2) CA3000988A1 (enExample)
IL (2) IL258498A (enExample)
MX (2) MX2018004109A (enExample)
WO (2) WO2017062500A2 (enExample)
ZA (2) ZA201802294B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018067589A1 (en) * 2015-10-05 2018-04-12 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
WO2023081858A1 (en) * 2021-11-04 2023-05-11 Skyhawk Therapeutics, Inc. Condensed-pyrazine amine derivatives for treating sca3

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020109039A1 (en) 2018-11-28 2020-06-04 Basf Se Pesticidal compounds
WO2020113178A1 (en) * 2018-11-30 2020-06-04 Celularity, Inc. Aromatic compounds for use in activating hematopoietic stem and progenitor cells
US20230355646A1 (en) 2020-09-17 2023-11-09 Resonac Corporation Autophagy activator
JPWO2022059776A1 (enExample) 2020-09-17 2022-03-24
TWI844795B (zh) 2020-09-17 2024-06-11 日商力森諾科股份有限公司 自噬活化劑
KR20230051238A (ko) 2020-09-17 2023-04-17 가부시끼가이샤 레조낙 오토파지 활성화제
CN112209888B (zh) * 2020-10-14 2024-02-02 河南中医药大学 一种4-芳巯基喹唑啉类化合物、制备方法和医药用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011143444A2 (en) 2010-05-14 2011-11-17 President And Fellows Of Harvard College Diphenylbutypiperidine autophagy inducers
WO2015079067A2 (en) 2013-11-29 2015-06-04 Velgene 3 Limited Various compounds as autophagy stimulants
WO2015106025A1 (en) 2014-01-09 2015-07-16 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Substituted benzoxazine and related compounds

Family Cites Families (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3272824A (en) 1962-12-06 1966-09-13 Norwich Pharma Co 4-amino-6, 7-di(lower) alkoxyquinolines
US3266990A (en) 1963-09-24 1966-08-16 Warner Lambert Pharmaceutical Derivatives of quinazoline
US3936461A (en) 1973-09-24 1976-02-03 Warner-Lambert Company Substituted 4-benzylquinolines
US4114939A (en) 1976-09-13 1978-09-19 Conco Inc. Vacuum pickup head
IL89027A (en) 1988-01-29 1993-01-31 Lilly Co Eli Quinazoline derivatives, process for their preparation and fungicidal, insecticidal and miticidal compositions containing them
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
GT198900008A (es) 1988-01-29 1990-07-17 Derivados de quinolina, quinazolina y cinolina.
WO1990005523A2 (en) 1988-11-15 1990-05-31 The Upjohn Company Phenanthrolinedicarboxylate esters, 4-aminoquinoline and isoquinoline derivatives as inhibitors of hiv reverse transcriptase
US5034393A (en) * 1989-07-27 1991-07-23 Dowelanco Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives
DE69231679T2 (de) 1991-04-03 2001-10-31 Korea Research Institute Of Chemical Technology, Daejeon 2-chinolinonderivate, verfahren zu deren herstellung und diese enthaltende fungizide und insektizide
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
JPH05213884A (ja) 1991-06-14 1993-08-24 Upjohn Co:The 新規な４−アミノキノリン類およびこれを有効成分とする高血圧・鬱血性心不全の予防・治療剤
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
DE4208254A1 (de) 1992-03-14 1993-09-16 Hoechst Ag Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid
AU4790893A (en) 1992-08-19 1994-03-15 Dowelanco Pyridylethoxy-, pyridylethylamino-, and pyridylpropyl-derivatives of quinoline and quinazoline as insecticides and fungicides
US5326766A (en) * 1992-08-19 1994-07-05 Dreikorn Barry A 4-(2-(4-(2-pyridinyloxy)phenyl)ethoxy)quinazoline and analogues thereof
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
US5650415A (en) 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
DE69618587T2 (de) 1995-06-07 2002-08-29 Sugen, Inc. Chinazoline und pharmazeutische zusammensetzungen
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
WO1997017329A1 (en) 1995-11-07 1997-05-15 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
DE69716916T2 (de) 1996-07-13 2003-07-03 Glaxo Group Ltd., Greenford Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
AU733551B2 (en) 1996-09-25 2001-05-17 Astrazeneca Ab Qinoline derivatives inhibiting the effect of growth factors such as VEGF
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6251912B1 (en) 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
WO1999031072A1 (en) 1997-12-18 1999-06-24 E.I. Du Pont De Nemours And Company Cyclohexylamine arthropodicides and fungicides
WO2000005234A1 (en) * 1998-07-22 2000-02-03 Suntory Limited NF-λB INHIBITORS CONTAINING INDAN DERIVATIVES AS THE ACTIVE INGREDIENT
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
EP1119567B1 (en) 1998-10-08 2005-05-04 AstraZeneca AB Quinazoline derivatives
CA2361057C (en) 1999-01-22 2010-04-06 Kazuo Kubo Quinoline derivatives and quinazoline derivatives
BRPI0017548B8 (pt) 1999-02-10 2023-05-02 Astrazeneca Ab Composto
GB9904103D0 (en) 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
GB9910577D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9910580D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9910579D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
JP2003509497A (ja) 1999-09-21 2003-03-11 アストラゼネカ アクチボラグ キナゾリン化合物とそれらを含有する医薬組成物
SK3822002A3 (en) 1999-09-21 2002-10-08 Astrazeneca Ab Quinazoline derivatives, process for the preparation thereof and their use
GB9930061D0 (en) 1999-12-20 2000-02-09 Glaxo Group Ltd Quinolone compounds for use in treating viral infections
US7135466B2 (en) 1999-12-24 2006-11-14 Kirin Beer Kabushiki Kaisha Quinoline and quinazoline derivatives and drugs containing the same
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
US7160889B2 (en) 2000-04-07 2007-01-09 Astrazeneca Ab Quinazoline compounds
NZ522696A (en) 2000-06-28 2004-08-27 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors
DE10042064A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Chinazoline, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6576644B2 (en) 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
AU2002210714A1 (en) 2000-11-02 2002-06-11 Astrazeneca Ab Substituted quinolines as antitumor agents
WO2002085895A1 (en) 2001-04-19 2002-10-31 Astrazeneca Ab Quinazoline derivatives
DE60208364T2 (de) 2001-04-27 2006-09-28 Kirin Beer K.K. Chinolinderivate mit einer azolylgruppe und chinazolinderivate
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
CA2454538A1 (en) 2001-06-22 2003-01-03 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same
US7501516B2 (en) 2001-07-16 2009-03-10 Astrazeneca Ab Quinoline derivatives and their use as tyrosine kinase inhibitors
WO2003033472A1 (en) 2001-10-17 2003-04-24 Kirin Beer Kabushiki Kaisha Quinoline or quinazoline derivatives inhibiting auto- phosphorylation of fibroblast growth factor receptors
EP1451156A4 (en) 2001-11-27 2005-05-25 Merck & Co Inc 4-AMINOCHINOLINVERBINDUNGEN
AU2002347360A1 (en) 2001-12-05 2003-06-17 Astrazeneca Ab Pharmaceutical compositions comprising benzofuranyl substituted 3-cyanoquinoline derivatives and their use for the treatment of solid tumours
AU2002365664A1 (en) 2001-12-05 2003-06-17 Astrazeneca Ab Quinoline derivatives as antitumour agents
GB0129099D0 (en) 2001-12-05 2002-01-23 Astrazeneca Ab Chemical compounds
WO2003048159A1 (en) 2001-12-05 2003-06-12 Astrazeneca Ab Quinoline derivatives
WO2003047584A1 (en) 2001-12-05 2003-06-12 Astrazeneca Ab Quinoline derivatives
WO2003047583A1 (en) 2001-12-05 2003-06-12 Astrazeneca Ab Pharmaceutical compositions comprising benzofuranyl substituted 3-cyanoquinoline derivatives and their use for the treatment of solid tumours
WO2003055866A1 (en) 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
CN1625555A (zh) 2002-02-01 2005-06-08 阿斯特拉曾尼卡有限公司 喹唑啉化合物
US7598258B2 (en) 2002-05-01 2009-10-06 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor
DE10221018A1 (de) 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
DE60327323D1 (de) 2002-07-09 2009-06-04 Astrazeneca Ab Chinazoline derivative und ihre anwendung in der krebsbehandlung
ES2400339T3 (es) 2002-07-15 2013-04-09 Symphony Evolution, Inc. Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer
CN1688549A (zh) 2002-08-23 2005-10-26 麒麟麦酒株式会社 具有TGFβ抑制活性的化合物和含所述化合物的药用组合物
EP1566379A4 (en) 2002-10-29 2005-11-09 Kirin Brewery CHINOLINE DERIVATIVES AND CHINAZOLINE DERIVATIVES AS INHIBITORS OF FLT3 AUTOPHOSPHORYLATION AND THE MEDICAL COMPOSITIONS CONTAINING THEREOF
GB0225579D0 (en) 2002-11-02 2002-12-11 Astrazeneca Ab Chemical compounds
US7462623B2 (en) 2002-11-04 2008-12-09 Astrazeneca Ab Quinazoline derivatives as Src tyrosine kinase inhibitors
PA8603801A1 (es) 2003-05-27 2004-12-16 Janssen Pharmaceutica Nv Derivados de la quinazolina
ATE440825T1 (de) * 2003-06-06 2009-09-15 Vertex Pharma Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern
CN1838950A (zh) * 2003-06-23 2006-09-27 神经化学（国际）有限公司 治疗蛋白质聚集疾病的方法
US20050026805A1 (en) 2003-07-14 2005-02-03 Ici Americas, Inc. Solvated nonionic surfactants and fatty acids
GB0318422D0 (en) 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
GB0322722D0 (en) 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
ATE446750T1 (de) 2003-12-18 2009-11-15 Janssen Pharmaceutica Nv 3-cyano-chinolin-derivate mit antiproliferativer wirkung
DE602004012891T2 (de) 2003-12-18 2009-04-09 Janssen Pharmaceutica N.V. Pyrido- und pyrimidopyrimidinderivate als anti-proliferative mittel
JP4503022B2 (ja) 2003-12-23 2010-07-14 ファイザー・インク 新規キノリン誘導体
CA2553729A1 (en) 2004-01-16 2005-08-04 Wyeth Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
CN101163684B (zh) 2005-02-23 2012-08-29 盐野义制药株式会社 具有酪氨酸激酶抑制作用的喹唑啉衍生物
WO2006097441A1 (en) * 2005-03-14 2006-09-21 Neurosearch A/S Potassium channel modulating agents and their medical use
CN101115736A (zh) * 2005-03-14 2008-01-30 神经研究公司 钾通道调节剂和它们的医药用途
JP2008537748A (ja) 2005-04-06 2008-09-25 エクセリクシス、インコーポレイテッド ｃ−Ｍｅｔモジュレーター及び使用方法
GB0509227D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
WO2006121767A2 (en) 2005-05-06 2006-11-16 Apath, Llc 4-aminoquinoline compounds for treating virus-related conditions
CN101316590B (zh) 2005-11-07 2011-08-03 卫材R&D管理有限公司 血管生成抑制剂和c-kit激酶抑制剂的组合使用
WO2007055513A1 (en) 2005-11-08 2007-05-18 Hanmi Pharm. Co., Ltd. Quinazoline derivatives as a signal transduction inhibitor and method for the preparation thereof
EP1948179A1 (en) 2005-11-11 2008-07-30 Boehringer Ingelheim International GmbH Quinazoline derivatives for the treatment of cancer diseases
CN102702194A (zh) 2005-12-21 2012-10-03 雅培制药有限公司 抗病毒化合物
CA2639936C (en) 2006-01-26 2014-06-17 Boehringer Ingelheim International Gmbh Process for preparing aminocrotonylamino-substituted quinazoline derivatives
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
WO2008006050A2 (en) 2006-07-07 2008-01-10 Govek Steven P Bicyclic heteroaryl inhibitors of pde4
US8673929B2 (en) 2006-07-20 2014-03-18 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
JP2010501570A (ja) 2006-08-23 2010-01-21 エックスティーエル バイオファーマシューティカルズ リミテッド ４−チオ置換キノリンおよびナフチリジン化合物
SI2084162T1 (sl) * 2006-10-23 2012-11-30 Sgx Pharmaceuticals Inc Biciklični triazoli kot modulatroji proteinskih kinaz
US8314087B2 (en) 2007-02-16 2012-11-20 Amgen Inc. Nitrogen-containing heterocyclyl ketones and methods of use
US8148532B2 (en) 2007-03-14 2012-04-03 Guoqing Paul Chen Spiro substituted compounds as angiogenesis inhibitors
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
DE102007032739A1 (de) 2007-07-13 2009-01-15 Merck Patent Gmbh Chinazolinamidderivate
US8143276B2 (en) 2007-08-22 2012-03-27 Xtl Biopharmaceuticals Ltd. 4-thio substituted quinoline and naphthyridine compounds
EP2178842A2 (en) 2007-08-22 2010-04-28 Abbott GmbH & Co. KG 4-benzylaminoquinolines, pharmaceutical compositions containing them and their use
NZ586946A (en) 2008-01-18 2012-06-29 Natco Pharma Ltd 6,7-Dialkoxy quinazoline derivatives useful for treatment of cancer related disorders
US20110045100A1 (en) 2008-03-05 2011-02-24 Georgetown University Antimalarial Quinolines and Methods of Use Thereof
PL2947072T3 (pl) 2008-03-17 2017-05-31 Ambit Biosciences Corporation 1-(3-(6,7-dimetoksychinazolin-4-yloksy)fenylo)-3-(5-(1,1,1-trifluoro-2-metylopropan-2-ylo)izoksazol-3-ilo)mocznik jako modulator kinazy RAF w leczeniu chorób nowotworowych
US7829574B2 (en) 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
CA2727103A1 (en) 2008-07-03 2010-01-07 Merck Patent Gmbh Naphthyridinones as aurora kinase inhibitors
AP2848A (en) 2008-08-14 2014-02-28 Univ Cape Town Quinoline compounds containing a dibemethin group
WO2010025451A2 (en) 2008-08-29 2010-03-04 Dow Agrosciences Llc 5,8-difluoro-4-(2-(4-(heteroaryloxy)-phenyl)ethylamino)quinazolines and their use as agrochemicals
IT1393351B1 (it) 2009-03-16 2012-04-20 Eos Ethical Oncology Science Spa In Forma Abbreviata Eos Spa Procedimento per la preparazione della 6-(7-((1-amminociclopropil)metossi)-6-metossichinolin-4-ilossi)-n-metil-1-naftammide e suoi intermedi di sintesi
WO2010107965A1 (en) 2009-03-19 2010-09-23 Boehringer Ingelheim International Gmbh Process for preparing sulfonyl quinolines
EP2408300B1 (en) 2009-03-21 2016-05-11 Sunshine Lake Pharma Co., Ltd. Amino ester derivatives, salts thereof and methods of use
ES2353093B1 (es) * 2009-05-20 2012-01-03 Consejo Superior De Investigaciones Científicas (Csic) Uso de derivados de quinazolinas y sus composiciones farmacéuticas en enfermedades neurodegenerativas.
KR20140015121A (ko) 2009-06-25 2014-02-06 암젠 인크 헤테로사이클릭 화합물 및 이의 용도
PH12012500097A1 (en) * 2009-07-21 2011-01-27 Shanghai Inst Organic Chem Potent small molecule inhibitors of autophagy, and methods of use thereof
WO2011014039A1 (en) * 2009-07-31 2011-02-03 Rohm And Haas Electronic Materials Korea Ltd. Novel organic electroluminescent compounds and organic electroluminescent device using the same
CN102844304B (zh) 2010-01-04 2014-12-31 日本曹达株式会社 含氮杂环化合物以及农园艺用杀菌剂
US8575203B2 (en) 2010-04-21 2013-11-05 Boehringer Ingelheim International Gmbh Chemical compounds
EP2588473A1 (en) 2010-06-30 2013-05-08 Amgen Inc. Nitrogen containing heterocyclic compounds as pik3 -delta inhibitors
US20120015942A1 (en) * 2010-07-19 2012-01-19 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
UY33549A (es) 2010-08-10 2012-01-31 Glaxo Group Ltd Quinolil aminas como agentes inhibidores de las quinasas
WO2012044993A1 (en) * 2010-09-30 2012-04-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds, pharmaceutical compositions, and methods of treating or preventing neurodegenerative diseases or disorders
US20140031547A1 (en) * 2010-12-14 2014-01-30 Electrophoretics Limited CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES
WO2012090179A2 (en) * 2010-12-30 2012-07-05 Lupin Limited Isoquinoline derivatives as cannabinoid receptor modulators
WO2012122011A2 (en) 2011-03-04 2012-09-13 Glaxosmithkline Llc Amino-quinolines as kinase inhibitors
US8664230B2 (en) 2011-03-17 2014-03-04 The Asan Foundation Pyridopyrimidine derivatives and use thereof
ITMI20110480A1 (it) 2011-03-25 2012-09-26 F I S Fabbrica Italiana Sint P A Procedimento per la preparazione di lapatinib e suoi sali
JP6027610B2 (ja) * 2011-07-19 2016-11-16 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環式化合物及びその使用
UY34451A (es) 2011-11-14 2013-05-31 Cephalon Inc Derivados de uracilo como inhibidores de la quinasa axl y c-met
CN102643268B (zh) 2011-12-30 2014-05-21 沈阳药科大学 喹啉类及噌啉类化合物及其应用
EP2828250B1 (en) 2012-03-19 2021-03-10 Imperial College Innovations Limited Quinazoline compounds and their use in therapy
US9193718B2 (en) 2012-03-26 2015-11-24 Fujian Institute Of Research On The Structure Of Matter, Chinese Academy Of Sciences Quinazoline derivative and application thereof
TW201425307A (zh) 2012-09-13 2014-07-01 Glaxosmithkline Llc 作為激酶抑制劑之胺基－喹啉類
US9024023B2 (en) 2013-01-14 2015-05-05 F.I.S.—Fabbrica Italiana Sintetici S.p.A. Efficient process for the preparation of lapatinib and salts thereof by means of new intermediates
CA2900652C (en) 2013-02-15 2021-05-04 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
MX2015012600A (es) 2013-03-15 2016-07-18 Rexahn Pharmaceuticals Inc Compuestos de tetrahidroisoquinolina-2-il-(quinazolina-4-il) metanona como inhibidores del crecimiento de células cancerígenas.
CN103232401B (zh) * 2013-04-12 2015-11-04 浙江工业大学 一种4-芳硫基喹唑啉类化合物的合成方法
WO2014182643A2 (en) 2013-05-07 2014-11-13 Inhibikase Therapeutics, Inc. Methods for treating hcv infection
HUE037512T2 (hu) 2013-05-13 2018-08-28 Shanghai hengrui pharmaceutical co ltd Cikloalkilsav-származék, eljárás elõállítására, és felhasználása gyógyszerként
CN105916506B (zh) 2013-11-20 2020-01-07 圣诺康生命科学公司 作为tam家族激酶抑制剂的喹唑啉衍生物
GB201321146D0 (en) 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
PE20170331A1 (es) 2014-03-24 2017-04-28 Guangdong Zhongsheng Pharmaceutical Co Ltd Derivados quinolina como inhibidores smo
FR3019819B1 (fr) 2014-04-09 2018-03-23 Centre National De La Recherche Scientifique (Cnrs) Composes cytotoxiques inhibiteurs de la polymerisation de la tubuline
CN106413715A (zh) 2014-04-22 2017-02-15 林伯士艾瑞斯公司 Irak抑制剂和其用途
CN104193728A (zh) * 2014-08-26 2014-12-10 北京大学深圳研究生院 流感病毒抑制剂及其应用
US20190112317A1 (en) * 2015-10-05 2019-04-18 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
US9853396B1 (en) 2016-12-05 2017-12-26 Delphi Technologies, Inc. Electrical plug having a flexible terminal retention feature

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011143444A2 (en) 2010-05-14 2011-11-17 President And Fellows Of Harvard College Diphenylbutypiperidine autophagy inducers
WO2015079067A2 (en) 2013-11-29 2015-06-04 Velgene 3 Limited Various compounds as autophagy stimulants
WO2015106025A1 (en) 2014-01-09 2015-07-16 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Substituted benzoxazine and related compounds

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018067589A1 (en) * 2015-10-05 2018-04-12 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
WO2023081858A1 (en) * 2021-11-04 2023-05-11 Skyhawk Therapeutics, Inc. Condensed-pyrazine amine derivatives for treating sca3

Also Published As

Publication number Publication date
US20180312527A1 (en) 2018-11-01
US20170210759A1 (en) 2017-07-27
WO2017062500A3 (en) 2017-05-26
MX2018004109A (es) 2018-09-27
US10865214B2 (en) 2020-12-15
JP2018530608A (ja) 2018-10-18
IL258498A (en) 2018-05-31
EP3523281A1 (en) 2019-08-14
KR20190058620A (ko) 2019-05-29
JP2020147597A (ja) 2020-09-17
US10487091B2 (en) 2019-11-26
EP3359526A4 (en) 2019-04-03
WO2018067589A1 (en) 2018-04-12
CA3000988A1 (en) 2017-04-13
ZA201901694B (en) 2020-10-28
EP3359526A2 (en) 2018-08-15
US20190112317A1 (en) 2019-04-18
AU2016333987A1 (en) 2018-05-10
BR112019006887A2 (pt) 2019-06-25
US20180312526A1 (en) 2018-11-01
EP3523281A4 (en) 2020-03-11
CN110023289A (zh) 2019-07-16
CA3037260A1 (en) 2018-04-12
BR112018006873A2 (pt) 2018-11-06
CN108473435A (zh) 2018-08-31
KR20180086187A (ko) 2018-07-30
US11008341B2 (en) 2021-05-18
ZA201802294B (en) 2020-06-24
US20200216469A1 (en) 2020-07-09
MX2019003805A (es) 2019-12-05
AU2017338769A1 (en) 2019-04-11
JP6740354B2 (ja) 2020-08-12
IL265750B (en) 2022-01-01
US20180319818A1 (en) 2018-11-08
JP2019529514A (ja) 2019-10-17
US11230558B2 (en) 2022-01-25
US11261199B2 (en) 2022-03-01
IL265750A (en) 2019-06-30

Similar Documents

Publication Publication Date Title
EP3359526A2 (en) Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
Cortes et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
Yang et al. Functional effects of muscle PGC-1alpha in aged animals
Liao et al. Sinomenine protects bone from destruction to ameliorate arthritis via activating p62Thr269/Ser272-Keap1-Nrf2 feedback loop
Dalal et al. Β-adrenergic receptor stimulation induces endoplasmic reticulum stress in adult cardiac myocytes: role in apoptosis
Weiler et al. Orally active 7-substituted (4-benzylphthalazin-1-yl)-2-methylpiperazin-1-yl] nicotinonitriles as active-site inhibitors of sphingosine 1-phosphate lyase for the treatment of multiple sclerosis
Wu et al. The ketone body β-hydroxybutyrate alleviates CoCrMo alloy particles induced osteolysis by regulating NLRP3 inflammasome and osteoclast differentiation
Aragón et al. Beta3-adrenoreceptor stimulation ameliorates myocardial ischemia-reperfusion injury via endothelial nitric oxide synthase and neuronal nitric oxide synthase activation
TWI342776B (en) Carbostyril derivatives and mood stabilizers for treating mood disorders
Yan et al. HDAC6 deacetylase activity is critical for lipopolysaccharide-induced activation of macrophages
CA2720908A1 (fr) Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules
Weber et al. Asenapine
US20220313628A1 (en) Methods for selecting phosphatase selective and non-selective phosphatase inhibitors
Tran et al. Long-term everolimus treatment in individuals with tuberous sclerosis complex: a review of the current literature
Becker et al. Ruxolitinib
Reyes Barcelo et al. Soluble aggregates of the amyloid-β peptide are trapped by serum albumin to enhance amyloid-β activation of endothelial cells
Liu et al. Differential effects of angiotensin II receptor blockers on Aβ generation
JP2009540003A (ja) Ａａ１ｒａの低頻度投与を含む腎機能の長期間にわたる改善
Liu et al. Extracellular calcium influx promotes antibacterial autophagy in Escherichia coli infected murine macrophages via CaMKKβ dependent activation of ERK1/2, AMPK and FoxO1
Kong et al. SIGMAR1 targets AMPK/ULK1 pathway to inhibit SH-SY5Y cell apoptosis by regulating endoplasmic reticulum stress and autophagy
Scherzer-Attali et al. Methylations of tryptophan-modified naphthoquinone affect its inhibitory potential toward Aβ aggregation
US20120010264A1 (en) Novel medicament for treating cognitive impairment
US20180243260A1 (en) Methods of treating cognitive and behavioral impairment in down syndrome and alzheimers disease patients
JP6830895B2 (ja) ストレス誘発性ｐ−ｔａｕを低下させるトリアゾロピリジン及びトリアゾロピリミジン
Takemori et al. Effects of angiotensin II type 1 receptor blocker and adiponectin on adipocyte dysfunction in stroke-prone spontaneously hypertensive rats

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16854245

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3000988

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2018/004109

Country of ref document: MX

Ref document number: 2018536715

Country of ref document: JP

Ref document number: 258498

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 122019019967

Country of ref document: BR

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018006873

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20187012344

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2016854245

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2016333987

Country of ref document: AU

Date of ref document: 20161005

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16854245

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 112018006873

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20180405